fda warning letters compounded semaglutide october 2025 Societies take stand against off-brand GLP-1s over safety concerns Semaglutide Patient Safety Updates |

Retatrutide: the triple agonist Retatrutide activates GLP-1, GIP, and glucagon receptors

The choice may ultimately come down to availability, given that tirzepatide is currently the only FDA-approved option

In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses glucagon release, thereby improving glycemic control

It shifts fat to a healthier pattern and can keep lean mass, so your waist may shrink while the scale barely moves

This article covers side effects reported in clinical trials, serious safety considerations still under study, and the practical clinical context for an informed conversation with a healthcare provider

Compounded medications (offered by TrimRx, MEDVi, Eden, and Willow) use the same active ingredients as brand-name drugs but are not FDA-approved finished products